Doxa AB (publ) (DOXA.ST)
SEK 0.57
(4.63%)
SEK 0.57
(4.63%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 280.8 Million SEK | 1434.43% |
| 2022 | 18.3 Million SEK | 103.33% |
| 2021 | 9 Million SEK | 78.71% |
| 2020 | 5.03 Million SEK | -34.64% |
| 2019 | 7.7 Million SEK | -11.08% |
| 2018 | 8.66 Million SEK | -20.04% |
| 2017 | 10.83 Million SEK | -23.13% |
| 2016 | 14.09 Million SEK | 73.58% |
| 2015 | 8.12 Million SEK | 153.34% |
| 2014 | 3.2 Million SEK | -58.24% |
| 2013 | 7.67 Million SEK | 52.9% |
| 2012 | 5.02 Million SEK | -47.27% |
| 2011 | 9.52 Million SEK | -76.58% |
| 2010 | 40.65 Million SEK | 684.9% |
| 2009 | 5.17 Million SEK | -87.19% |
| 2008 | 40.42 Million SEK | 33.33% |
| 2007 | 30.31 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 385.9 Million SEK | 1.1% |
| 2024 Q1 | 381.7 Million SEK | 35.93% |
| 2023 Q4 | 280.8 Million SEK | 940.0% |
| 2023 Q3 | 27 Million SEK | -47.78% |
| 2023 Q2 | 51.7 Million SEK | 155.94% |
| 2023 Q1 | 20.2 Million SEK | 10.38% |
| 2023 FY | 280.8 Million SEK | 1434.43% |
| 2022 Q1 | 87.3 Million SEK | 870.0% |
| 2022 FY | 18.3 Million SEK | 103.33% |
| 2022 Q3 | 6.5 Million SEK | -77.03% |
| 2022 Q4 | 18.3 Million SEK | 181.54% |
| 2022 Q2 | 28.3 Million SEK | -67.58% |
| 2021 Q2 | 10.4 Million SEK | 76.27% |
| 2021 FY | 9 Million SEK | 78.71% |
| 2021 Q3 | 4.8 Million SEK | -53.85% |
| 2021 Q4 | 9 Million SEK | 87.5% |
| 2021 Q1 | 5.9 Million SEK | 17.16% |
| 2020 Q4 | 5.03 Million SEK | -66.43% |
| 2020 Q3 | 15 Million SEK | 4.17% |
| 2020 Q2 | 14.4 Million SEK | 25.22% |
| 2020 Q1 | 11.5 Million SEK | 49.25% |
| 2020 FY | 5.03 Million SEK | -34.64% |
| 2019 Q3 | 7.6 Million SEK | 94.87% |
| 2019 Q4 | 7.7 Million SEK | 1.38% |
| 2019 FY | 7.7 Million SEK | -11.08% |
| 2019 Q1 | 8.9 Million SEK | 2.71% |
| 2019 Q2 | 3.9 Million SEK | -56.18% |
| 2018 Q3 | 8.8 Million SEK | -8.33% |
| 2018 Q4 | 8.66 Million SEK | -1.53% |
| 2018 Q2 | 9.6 Million SEK | 1.05% |
| 2018 FY | 8.66 Million SEK | -20.04% |
| 2018 Q1 | 9.5 Million SEK | -12.34% |
| 2017 Q2 | 18.1 Million SEK | -1.09% |
| 2017 Q1 | 18.3 Million SEK | 29.81% |
| 2017 FY | 10.83 Million SEK | -23.13% |
| 2017 Q3 | 19.9 Million SEK | 9.94% |
| 2017 Q4 | 10.83 Million SEK | -45.54% |
| 2016 Q3 | 11.9 Million SEK | 21.43% |
| 2016 FY | 14.09 Million SEK | 73.58% |
| 2016 Q4 | 14.09 Million SEK | 18.47% |
| 2016 Q2 | 9.8 Million SEK | 13.95% |
| 2016 Q1 | 8.6 Million SEK | 5.89% |
| 2015 FY | 8.12 Million SEK | 153.34% |
| 2015 Q3 | 2.6 Million SEK | -18.75% |
| 2015 Q2 | 3.2 Million SEK | -13.51% |
| 2015 Q1 | 3.7 Million SEK | 15.41% |
| 2015 Q4 | 8.12 Million SEK | 212.38% |
| 2014 FY | 3.2 Million SEK | -58.24% |
| 2014 Q4 | 3.2 Million SEK | 68.74% |
| 2014 Q3 | 1.9 Million SEK | -20.83% |
| 2014 Q2 | 2.4 Million SEK | -11.11% |
| 2014 Q1 | 2.7 Million SEK | -64.83% |
| 2013 Q4 | 7.67 Million SEK | 148.69% |
| 2013 Q3 | 3.08 Million SEK | 30.2% |
| 2013 FY | 7.67 Million SEK | 52.9% |
| 2013 Q2 | 2.37 Million SEK | 0.0% |
| 2012 Q4 | 5.02 Million SEK | 0.0% |
| 2012 FY | 5.02 Million SEK | -47.27% |
| 2011 FY | 9.52 Million SEK | -76.58% |
| 2010 FY | 40.65 Million SEK | 684.9% |
| 2009 FY | 5.17 Million SEK | -87.19% |
| 2008 FY | 40.42 Million SEK | 33.33% |
| 2007 FY | 30.31 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AddLife AB (publ) | 7.78 Billion SEK | 96.393% |
| Biotage AB (publ) | 1.27 Billion SEK | 77.959% |
| Bonesupport Holding AB (publ) | 143.63 Million SEK | -95.49% |
| Elekta AB (publ) | 21.61 Billion SEK | 98.701% |
| iZafe Group AB (publ) | 9.26 Million SEK | -2932.07% |
| Ortivus AB (publ) | 55.4 Million SEK | -406.85% |
| Ortivus AB (publ) | 55.4 Million SEK | -406.85% |
| Q-linea AB (publ) | 42.34 Million SEK | -563.203% |
| S2Medical AB (publ) | 19.74 Million SEK | -1321.812% |
| Synsam AB (publ) | 5.52 Billion SEK | 94.914% |